Document:

<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

                                                                   Exhibit 10.31

                       COLLABORATION AND LICENSE AGREEMENT

                                     BETWEEN

                           HUMAN GENOME SCIENCES, INC.

                                       AND

                                   DYAX CORP.

                                 March 17, 2000
<PAGE>

TABLE OF CONTENTS

1.   DEFINITIONS..............................................................2
2.   LICENSE GRANTS AND NONSUIT...............................................5
3.   PAYMENTS AND ROYALTIES...................................................6
4.   COLLABORATION, TECHNOLOGY TRANSFER, TRAINING AND SUPPORT................10
5.   CONFIDENTIALITY.........................................................11
6.   INTELLECTUAL PROPERTY OWNERSHIP.........................................12
7.   PATENT PROSECUTION AND LITIGATION.......................................13
8.   STATEMENTS AND REMITTANCES..............................................15
9.   TERM AND TERMINATION....................................................16
10.  WARRANTIES AND REPRESENTATIONS..........................................17
11.  INDEMNIFICATION.........................................................18
12.  FORCE MAJEURE...........................................................20
13.  DISPUTE RESOLUTION......................................................20
14.  ENTIRE AGREEMENT........................................................21
15.  NOTICES.................................................................22
16.  ASSIGNMENT AND CHANGE OF CONTROL........................................22
17.  COUNTERPARTS............................................................23
18.  WAIVER..................................................................23
19.  INDEPENDENT RELATIONSHIP................................................23
20.  FURTHER ACTIONS.........................................................23
     EXHIBIT A...............................................................27
     EXHIBIT B...............................................................29
     EXHIBIT C...............................................................30

                                       1
<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

                       COLLABORATION AND LICENSE AGREEMENT

      This Agreement ("Agreement") dated as of the 17th of March 2000 (the
"Effective Date"), is entered into by Human Genome Sciences, Inc. ("HGS"), a
Delaware corporation, having its principal offices at 9410 Key West Avenue,
Rockville, Maryland 20850, and Dyax Corp., ("DYAX"), a Delaware corporation
having its principal offices at One Kendall Square, Bldg. 600, Suite 623,
Cambridge, Massachusetts 02139. The parties hereby agree as follows:

1. DEFINITIONS

      1.1 "AFFILIATE" shall mean any individual or entity directly or indirectly
controlling, controlled by or under common control with, the specified
individual or entity. For purposes of this Agreement, the direct or indirect
ownership of fifty percent (50%) or more of the outstanding voting securities of
an entity, or the right to receive fifty percent (50%) or more of the profits or
earnings of an entity shall be deemed to constitute control.

      1.2 "COLLABORATION PRODUCT" shall mean any product incorporating or
derived from any peptide or antibody compound, and the sequence contained
therein, discovered by DYAX using the DYAX TECHNOLOGY during the
COLLABORATION TERM, and that binds to an HGS TARGET.

      1.3 "COLLABORATION TERM" shall mean the period beginning on the Effective
Date and ending on March 15, 2005.

      1.4 "CONFIDENTIAL INFORMATION" means any scientific, technical, trade or
business information disclosed by one Party to the other Party which is (a)
disclosed in writing or other tangible form and labeled "CONFIDENTIAL" at the
time of disclosure or (b) disclosed verbally and identified as confidential at
the time of disclosure and subsequently summarized and confirmed in writing as
confidential within thirty (30) days of such oral disclosure. "Confidential
Information" does not include information which (a) was known to the Receiving
Party at the time it was disclosed, other than by previous disclosure by the
Disclosing Party, as evidenced by written records at the time of disclosure: (b)
at the time of disclosure or later becomes publicly known under circumstances
involving no breach of this Agreement; (c) is lawfully and in good faith made
available to the Receiving Party by a third party who did not derive it from the
Disclosing Party and who imposes no obligation of confidence on the Receiving
Party; (d) is developed by the Receiving Party independent of any disclosure by
the Disclosing Party, as evidenced by the Receiving Party's written records; or
(e) is required by law or regulation to be disclosed.

      1.5 "DIAGNOSTIC FIELD" shall mean all in vitro research, analysis,
detection or diagnostic uses, and not for any in vivo diagnostic, therapeutic,
purification or separations, agricultural, industrial enzyme or other uses.

      1.6 "DYAX FIELD" shall mean all agricultural, industrial enzyme, and
purification and separation uses.

                                       2
<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

      1.7 "DYAX PATENT RIGHTS" shall mean any and all claims of United States
Patent Nos. 5,223,409, 5,403,484, 5,571,698, and 5,837,500 (collectively, the
"U.S. Patents"), reissues, reexaminations, renewals and extensions thereof, and
all continuations, continuations-in-part and divisionals of the applications for
such U.S. patents and all counterparts thereto in countries outside the United
States, which patents and patent applications as of the Effective Date are
listed in Exhibit A. Patent Rights shall exclude (i) Claim 66 in U.S. Patent
No. 5,223,409 to the extent that it covers DNA molecules encoding single
chain antibodies or (ii) any claim to specific protein or peptide sequences,
or nucleic acids encoding the same, that bind to a specific biological or
molecular target.

      1.8 "DYAX TECHNOLOGY" shall mean collectively the ************* phage
libraries listed in Exhibit B, ************* (the "Dyax Libraries") and
associated reagents, protocols, and know-how of DYAX relating to the Dyax
Libraries that are transferred to HGS in accordance with this Agreement, and any
IMPROVEMENTS and associated reagents, protocols and know-how relating to the
Dyax Libraries.

      1.9 "FIELD OF USE" shall mean the THERAPEUTIC FIELD, DIAGNOSTIC FIELD,
and/or RESEARCH REAGENT FIELD, and shall not include any in vivo diagnostic
uses other than as provided in Section 1.27 herein, or any purification or
separations, agricultural, industrial enzymes or any other uses.

      1.10 "FTE" shall mean a full time equivalent employee assigned to HGS
pursuant to Paragraph 4.4.

      1.11 "HGS PATENT RIGHTS" shall mean PATENT RIGHTS which HGS owns or which
HGS is licensed to use and which directly relate to a target at the Effective
Date or during the TECHNOLOGY TERM.

      1.12 "HGS TARGET" shall mean a target for which HGS has HGS PATENT RIGHTS.

      1.13 "IMAGING FIELD" shall mean all in vivo detection or diagnostic uses,
and not for use in any Therapeutic Field or Diagnostic Field.

      1.14 "IMPROVEMENTS" shall mean any improvement to the Dyax Libraries made
by DYAX during the COLLABORATION TERM or by HGS during the TECHNOLOGY TERM,
such as an increase in the phage library diversity, efficiency of display,
infectivity of the phage and the like, and each phage library resulting from
such improvements.

      1.15 "IND" shall mean an Investigational New Drug application filed with
the Food and Drug Administration in the United States of America, or the
successor agency thereto (the "FDA"), or any equivalent filing with the
applicable foreign regulatory authority to commence human clinical testing of a
product in any other country.

      1.16 "MAJOR COUNTRY" shall mean the United States, Canada, Japan, United
Kingdom, France, Germany, Italy or Spain.

      1.17 "NET REVENUES" shall mean all payments received by HGS and its
AFFILIATES from THIRD PARTIES, whether cash or other consideration, from the
license or sublicense of a COLLABORATION PRODUCT OR NON-COLLABORATION PRODUCT,
less any payments made to reimburse HGS or its AFFILIATES for any actual costs
incurred.

                                       3
<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

      1.18 "NET SALES" shall mean the amounts invoiced on the sales of a product
by a Party and its AFFILIATES and their distributors to independent, unrelated
third parties in bona fide arms' length transactions, less the following
deductions properly documented actually allowed and taken by such third parties
and not otherwise recovered by or reimbursed by the Party or its AFFILIATES: (a)
trade, cash and quantity discounts, including charge backs; (b) taxes on sales
(such as sales or use taxes) to the extent added to the sales price and set
forth separately as such in the total amount invoiced; (c) freight, insurance
and other transportation charges to the extent added to the sales prices and set
forth separately as such in the total amount invoiced; (d) amounts repaid or
credited by reason of rejections, defects or returns, or because of retroactive
price reductions, or due to governmental laws or regulations requiring rebates;
(e) import duties; and means further the amount of fair market value of all
other consideration received by the Party or its AFFILIATES in respect of the
product, whether such consideration is in cash, payments in kind, exchange or
other forms; but does not mean sales of the product between or among a Party and
its AFFILIATES. In the event a product is sold in combination with other active
components ("Combination Product"), NET SALES for purposes of royalty payments
on the Combination Products shall be calculated *************.

      1.19 "NON-COLLABORATION PRODUCT" shall mean any product incorporating
or derived from any peptide or antibody compound, and the sequence contained
therein, discovered by HGS using the DYAX TECHNOLOGY during the TECHNOLOGY
TERM, and that binds to an HGS TARGET.

      1.20 "NON-DYAX PRODUCT" shall mean any product discovered by HGS not using
DYAX TECHNOLOGY, but using inventions claimed in DYAX PATENT RIGHTS and for
which HGS requires a license pursuant this Agreement to DYAX PATENT RIGHTS.
A NON-DYAX PRODUCT shall not include a product for which HGS already has a
license to DYAX PATENT RIGHTS through a third party.

      1.21 "PATENT RIGHTS" shall mean patent applications or patents, author
certificates, inventor certificates, utility certificates, improvement patents,
and models and certificates of addition, and all foreign counterparts of them
and includes divisions, renewals, continuations, continuations-in-part,
extensions, reissues, substitutions, confirmations, registrations,
revalidations, or additions of or to them as well as any supplementary
protection certificate or any other post patent expiration extension of patent
protection in respect to them.

      1.22 "RESEARCH PROGRAM IP" shall mean all results of the collaboration
between DYAX AND HGS described in Article 4 herein, including all materials and
data, and all PATENT RIGHTS covering such results; but shall exclude general
know-how developed by DYAX, DYAX TECHNOLOGY and IMPROVEMENTS, and subject to
any mutual agreement pursuant to Paragraph 4.8.

      1.23 "RESEARCH REAGENT FIELD" shall mean the use of one or more
peptides, antibodies, or antibody-antigen or peptide-target combinations
(whether in a micro array format or other format) for research purposes.

      1.24 "SB/HGS LICENSE AGREEMENT" shall mean the SB/HGS License Agreement
dated June 28, 1996 between SmithKline Beecham Corporation, SmithKline Beecham
p.l.c., and Human Genome Sciences, Inc., and all predecessor and successor
agreements, in each case as amended or supplemented after the date hereof,
including the SB/HGS Diagnostic License Agreement dated July 24, 1997.

                                       4
<PAGE>

      1.25 "SPC" shall mean a right based upon an underlying patent such as a
Supplementary Protection Certificate.

      1.26 "TECHNOLOGY TERM" shall mean the period beginning on the Effective
Date and ending on March 15, 2010.

      1.27 "THERAPEUTIC FIELD" shall mean all human therapeutic and
prophylactic uses, and any in vivo diagnostic uses for an HGS TARGET which is
necessary for HGS' successful commercialization of a human therapeutic or
prophylactic COLLABORATION PRODUCTION-COLLABORATION PRODUCT or NON-DYAX
PRODUCT.

      1.28 "THIRD PARTY" shall mean any party, other than HGS or DYAX or an
AFFILIATE of DYAX or HGS.

2. LICENSE GRANTS AND NONSUIT

      2.1 DYAX grants to HGS a royalty-free non-exclusive, worldwide license
(without the right to grant sublicenses) to DYAX PATENT RIGHTS,DYAX TECHNOLOGY
and IMPROVEMENTS for HGS to perform research and development solely on HGS'
behalf in the FIELD OF USE during the TECHNOLOGY TERM.

      2.2 DYAX hereby grants to HGS a non-exclusive, worldwide license to DYAX
PATENT RIGHTS, DYAX TECHNOLOGY and IMPROVEMENTS to research, develop, make, have
made, use, import, offer to sell and sell COLLABORATION PRODUCTS and
NON-COLLABORATION PRODUCTS in the FIELD OF USE and to sublicense, solely the
research, development, manufacture, use, importation and sale of such
COLLABORATION PRODUCTS and NON-COLLABORATION PRODUCTS in the FIELD OF USE.

      2.3 DYAX hereby grants to HGS an exclusive, worldwide license to research,
develop, make, have made, use, import, offer to sell and sell COLLABORATION
PRODUCTS in the FIELD OF USE and to sublicense the research, development,
manufacture, use, importation and sale of such COLLABORATION PRODUCTS in the
FIELD OF USE.

      2.4 DYAX hereby grants to HGS a non-exclusive, worldwide license to DYAX
PATENT RIGHTS to research, develop, make, have made, use, import, offer to sell
and sell NON-DYAX PRODUCTS in the FIELD OF USE and to sublicense solely the
research, development, manufacture, use, importation and sale of such NON-DYAX
PRODUCTS in the FIELD OF USE.

      2.5 Effective July 1, 2001, and subject to conditions set out below,
HGS hereby agrees to grant to DYAX an exclusive worldwide license RESEARCH
PROGRAM IP to research, develop, make, have made, use, import, offer to sell
and sell COLLABORATION PRODUCTS in the IMAGING FIELD, whenever discovered,
and to sublicense the research, development, manufacture, use, importation
and sale of such COLLABORATION PRODUCTS in the IMAGING FIELD. If a license to
any HGS PATENT is needed to effectuate this license for any product in the
IMAGING FIELD, HGS agrees to grant DYAX a non-exclusive worldwide license to
such HGS PATENT.

            2.5.1 In the event that DYAX wishes to obtain a license pursuant to
this Paragraph 2.5 to a COLLABORATION PRODUCT in the IMAGING FIELD, DYAX shall

                                       5
<PAGE>

submit a written notice to HGS identifying the COLLABORATION PRODUCT and the HGS
TARGET to which it binds.

            2.5.2 Within thirty (30) days after receipt of such notice, HGS
shall notify DYAX in writing if HGS does not have the right or the obligation
as defined in Paragraph 2.5.3 to grant DYAX the license under Paragraph 2.5
for such COLLABORATION PRODUCT. If HGS does not have such right or
obligation, HGS shall not be obligated to grant to DYAX the exclusive license
under Paragraph 2.5 for such product. If HGS has the right and the obligation
to grant such a license, but is required to submit a diagnostic research plan
to SB pursuant to the SB/HGS LICENSE AGREEMENT, HGS shall promptly submit
such plan and shall notify DYAX as soon as such plan is submitted. If HGS is
the first between HGS and SB to submit such a plan directed to HGS TARGET,
HGS shall promptly notify DYAX and shall grant the license pursuant to
Paragraph 2.5 for the COLLABORATION PRODUCT. DYAX shall provide to HGS such
reasonable assistance as may be required to submit such plan and any required
annual reports. Unless HGS timely notifies DYAX in writing that it does not
have such a right or obligation or that it is submitting a diagnostic
research plan, the exclusive license grant under Paragraph 2.5 for
COLLABORATION PRODUCT shall be effective upon the expiration of such thirty
(30) day period.

            2.5.3 HGS shall not have the right or the obligation to grant DYAX a
license to research, develop, make, have made, use, import, offer to sell and
sell COLLABORATION PRODUCTS in the IMAGING FIELD, if (1) HGS has previously
granted a license or an option to a license under part or all of HGS PATENT
RIGHTS to a THIRD PARTY for use of the HGS TARGET and/or compounds that bind
to the target in the field of human diagnostics; (2) use of the COLLABORATION
PRODUCT in the IMAGING FIELD is necessary for HGS' successful
commercialization of the therapeutic uses of such product, as set forth in
Section 1.27; or (3) HGS has an in-house project with respect to the
applicable HGS TARGET, for which no DYAX TECHNOLOGY is used and for which no
license to DYAX PATENT RIGHTS would be required in the absence of this
Agreement, and as evidenced by its records has committed resources to such
project within the last 6 months prior to the notice by DYAX. Nothing in this
Section 2.5 shall be deemed as DYAX granting HGS any rights in the IMAGING
FIELD, except as set forth in the THERAPEUTIC FIELD.

      2.6 As requested by DYAX with respect to a NON-COLLABORATION PRODUCT,
HGS agrees to discuss with DYAX the possibility of granting to DYAX a license
to RESEARCH PROGRAM IP to research, develop, make, have made, use, import
offer to sell and sell NON-COLLABORATION PRODUCTS in the IMAGING FIELD but
HGS shall have no obligation to grant such license.

      2.7 If not prohibited by the SB/HGS LICENSE AGREEMENT with respect to
HGS TARGETS, HGS grants to DYAX an exclusive worldwide, royalty-free license
with the right to sublicense to RESEARCH PROGRAM IP to research, develop,
make, have made, use, import, offer to sell and sell products in the DYAX
FIELD, and a non-exclusive worldwide, royalty-free license with the right to
sublicense to RESEARCH PROGRAM IP to research, develop, make, have made, use,
import, offer to sell and sell products in all fields other than the FIELD OF
USE and the IMAGING FIELD. No license to any HGS PATENT RIGHTS is granted by
this Paragraph, even if such license is necessary to effectuate the license
granted pursuant to this Paragraph, and no such license to any HGS PATENT
RIGHTS shall be implied.

     2.8 HGS agrees not to enforce against DYAX any patent right owned or
controlled by HGS that arose or will arise from HGS' practice of any of the
DYAX TECHNOLOGY or any of the inventions claimed in the DYAX PATENT RIGHTS,
that DYAX may infringe in practicing the DYAX TECHNOLOGY or the inventions
claimed in the DYAX PATENT RIGHTS. Nothing in this Paragraph 2.8 is intended
to grant DYAX any rights to nonsuit with respect to any claim in any patent
right owned or controlled by HGS that claims any compound or sequence or
product. The parties agree that the covenant not to sue in this Paragraph is
an obligation that transfers with the sale or disposition by HGS of the
applicable patent right.

     2.9 Prior to outlicensing (such as through a sublicense) a COLLABORATION
PRODUCT or a NON-COLLABORATION PRODUCT to a THIRD PARTY in the FIELD OF USE,
HGS agrees to notify DYAX of its intent to outlicense such product, and DYAX
shall have the right to submit a bid for such outlicense. Other than HGS'
obligation to notify DYAX, HGS shall have no obligation to accept a bid from
DYAX or to enter into negotiations with DYAX, and shall be free to outlicense
such product to any THIRD PARTY in the FIELD OF USE on whatever terms HGS
chooses, consistent with HGS' obligations under this Agreement.

      2.10 HGS agrees to use commercially reasonable efforts to research and
development, obtain any necessary governmental approvals, market and sell
COLLABORATION PRODUCTS in a MAJOR COUNTRY, and after the end of the
COLLABORATION TERM, upon DYAX's request to provide DYAX with written updates on
such efforts.

3. PAYMENTS AND ROYALTIES

      3.1 In consideration of the licenses and rights of ownership granted
and to be granted hereunder, HGS will pay to DYAX within ten (10) days of the
Effective Date six million U.S. dollars ($6,000,000), but not later than
March 31, 2000. The parties agree that such amount represents a collaboration
commitment of resources and costs of first year start-up activities (such
activities to be managed by the Steering Committee) of two million U.S.
dollars, a paid-up signing and annual fees under the DYAX PATENT RIGHTS of
five hundred thousand U.S. dollars, and a paid up signing and annual fees
under the DYAX TECHNOLOGY of three million five hundred thousand U.S. dollars.

      HGS Therapeutic Products

      3.2 Subject to Paragraphs 3.4 and 3.11, for each COLLABORATION PRODUCT or
NON-COLLABORATION PRODUCT which is sold in the THERAPEUTIC FIELD, HGS shall pay
to DYAX the following royalties and milestone payments (which milestone
payments under this Paragraph 3.2 shall be due and payable within thirty (30)
days after the applicable milestone event is achieved by or on behalf of HGS
or its AFFILIATE):

                                       6
<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

            (a)   ************* upon the filing of an IND or upon the first in
                  vivo testing in humans for such COLLABORATION PRODUCT or
                  NON-COLLABORATION PRODUCT;

            (b)   ************* upon start of a Phase III clinical trial (as
                  defined in Section 3.14) for such COLLABORATION PRODUCT or
                  NON-COLLABORATION PRODUCT;

            (c)   ************* upon the first regulatory approval in a MAJOR
                  COUNTRY of such COLLABORATION PRODUCT or NON-COLLABORATION
                  PRODUCT for commercial sale;

            (d)   ************* upon the second regulatory approval in a
                  MAJOR COUNTRY of such COLLABORATION PRODUCT or
                  NON-COLLABORATION PRODUCT for commercial sale; and

            (e)   a royalty ************* of such COLLABORATION PRODUCT or
                  NON-COLLABORATION PRODUCT sold by HGS or its AFFILIATES.

HGS shall have no obligation to pay each milestone payment to DYAX under this
Paragraph 3.2. more than once for each different COLLABORATION PRODUCT or
NON-COLLABORATION PRODUCT. For purposes of determining the milestone payments
owing under this Paragraph 3.2, a COLLABORATION PRODUCT or NON-COLLABORATION
PRODUCT containing an antibody directed to an HGS Target shall constitute the
same COLLABORATION PRODUCT or NON-COLLABORATION PRODUCT as any other
COLLABORATION PRODUCT or NON-COLLABORATION PRODUCT, if such COLLABORATION
PRODUCT or NON-COLLABORATION PRODUCT contains an antibody directed to the
same HGS TARGET as the other COLLABORATION PRODUCT or NON-COLLABORATION
PRODUCT, without regard to the formulation or means of administration
thereof. Similarly, a COLLABORATION PRODUCT or NON-COLLABORATION PRODUCT
containing a peptide directed to an HGS Target shall constitute the same
COLLABORATION PRODUCT or NON-COLLABORATION PRODUCT as any other COLLABORATION
PRODUCT or NON-COLLABORATION PRODUCT, if such COLLABORATION PRODUCT or
NON-COLLABORATION PRODUCT contains a peptide directed to the same HGS TARGET
as the other COLLABORATION PRODUCT or NON-COLLABORATION PRODUCT, without
regard to the formulation or means of administration thereof. If HGS develops
and markets separate antibody and peptide products directed to the same HGS
TARGET, HGS shall have an obligation to pay a full set of separate milestone
payments for each class of products.

      3.3 Subject to Paragraphs 3.4 and 3.11, if HGS outlicenses a COLLABORATION
PRODUCT or NON-COLLABORATION PRODUCT to a THIRD PARTY for sale in the
THERAPEUTIC FIELD, HGS shall pay to DYAX, in lieu of milestones and royalties,
the following:

            (a)   ************* NET REVENUE received by HGS from such
                  outlicense, if the product is outlicensed prior to payment of
                  the milestone owed pursuant to Paragraph 3.2(a);

            (b)   ************* NET REVENUE received by HGS from such
                  outlicense, if the product is outlicensed after payment of the
                  milestone owed pursuant to Paragraph 3.2(a), but prior to
                  payment of the milestone owed pursuant to Paragraph 3.2(b);

            (c)   ************* NET REVENUE received by HGS from such
                  outlicense, if the product is outlicensed after payment of the
                  milestone owed pursuant to Paragraph 3.2(b).

      3.4 For the sole purpose of determining royalties, milestones or
revenue owed pursuant to Paragraphs 3.2 and 3.3, if a COLLABORATION PRODUCT
or NON-COLLABORATION PRODUCT is jointly developed and marketed pursuant to
the SB/HGS LICENSE AGREEMENT by HGS and SB together, SB shall be considered
to be an AFFILIATE of HGS and the milestones and royalties set forth in
Paragraph 3.2 shall apply to such product.

HGS In Vitro Diagnostic and Research Reagent Products

      3.5 Subject to Paragraph 3.11, for each COLLABORATION PRODUCT or
NON-COLLABORATION PRODUCT which is sold by HGS or its AFFILIATES in the
DIAGNOSTIC FIELD or the RESEARCH REAGENT FIELD, HGS shall pay to DYAX the
following royalty:

            (a)   a royalty of ************* of NET SALES of such COLLABORATION
                  PRODUCT or NON-COLLABORATION PRODUCT sold by HGS or its
                  AFFILIATES.

      No milestones shall be owed on such products.

                                       7
<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

      3.6 Subject to Paragraph 3.11, if HGS outlicenses a COLLABORATION PRODUCT
or NON-COLLABORATION PRODUCT to a THIRD PARTY for sale in the DIAGNOSTIC FIELD
or the RESEARCH REAGENT FIELD, HGS shall pay to DYAX, in lieu of the royalty set
forth in Paragraph 3.5, the following:

            (a)   ************* the portion of NET REVENUES received by HGS from
                  such outlicense, which portion is attributable to the
                  product outlicensed. The portion of revenue attributable to
                  the product shall be calculated by multiplying the revenue
                  received by the fraction A/(A+B), where A is the gross
                  selling price of the product sold separately (i.e., without
                  any other components) and B is the gross selling price of
                  the components. In the event that no such separate sales
                  are made of the product components, the portion shall be
                  calculated by multiplying the revenue by the fraction
                  C/(C+D) where C is the fully allocated cost of the product
                  (not including the other components) and D is the fully
                  allocated cost of the other components such costs being
                  determined using generally accepted accounting procedures
                  consistently applied. Thus, for example, if a research
                  reagent is sold as a research chip, and the fully allocated
                  cost of the chip is X and the fully allocated cost of the
                  antibody on the chip, which antibody is a NON-COLLABORATION
                  PRODUCT, is Y, ************.

      HGS Non-Dyax Products

      3.7 Subject to Paragraphs 3.8 and 3.12, for each NON-DYAX PRODUCT which is
sold by HGS, its AFFILIATES or its licensees, HGS shall pay to DYAX the
following royalty:

            (a)   a royalty of ************* NET SALES of such NON-DYAX PRODUCT
                  sold by HGS, its AFFILIATES or its licensees in the
                  THERAPEUTIC FIELD; and

            (b)   a royalty of ************* NET SALES of such NON-DYAX PRODUCT
                  sold by HGS, its AFFILIATES or its licensees in the DIAGNOSTIC
                  FIELD or the RESEARCH REAGENT FIELD.

      3.8 In the event HGS is required to pay royalties on NET SALES of a
NON-DYAX PRODUCT to any THIRD PARTY as a result of any patent license
required for HGS to practice the inventions claimed in the DYAX PATENT
RIGHTS, HGS shall be permitted to offset such royalty payment against the
royalty payments due DYAX on the same NET SALES, provided, however, that this
offset shall be applied on a pro rata basis with any other offsets permitted
by the THIRD PARTY, and provided further that no royalty payment due on any
NET SALES shall be reduced by more than *************.

      DYAX Products in the Imaging Field

      3.9 Subject to Paragraph 3.13, for each COLLABORATION PRODUCT which is
sold by DYAX or its AFFILIATES in the IMAGING FIELD, DYAX shall pay to HGS the
following royalty:

            (a)   a royalty of ************* NET SALES of such COLLABORATION
                  PRODUCT sold by DYAX or its AFFILIATES.

      No milestones shall be owed on such products.

      3.10 Subject to Paragraph 3.13, if DYAX outlicenses a COLLABORATION
PRODUCT to a THIRD PARTY for sale in the IMAGING FIELD, DYAX shall pay to HGS,
in lieu of the royalty set forth in Paragraph 3.5, the following:

            (a)   ************* NET REVENUES received by DYAX from such
                  outlicense, which portion is attributable to the product
                  outlicensed. *************.

      Miscellaneous

      3.11 Royalty and revenue obligations under Paragraphs 3.2, 3.3, 3.5 and
3.6, with respect to COLLABORATION OR NON-COLLABORATION PRODUCT, shall terminate
on a

                                       8
<PAGE>

country-by-country basis and on a product by product basis on the later of (i)
ten (10) years after first country-wide launch of such product in such
country or (ii) expiration of the last to expire patent (whether or not owned
by HGS) on the relevant product licensed to HGS under this Agreement which
covers the making, having made, importing, offering to sell or using or
selling of such product in the country in which such product was developed,
made, sold or used.

      3.12 Royalty obligations under Paragraph 3.7, with respect to a NON-DYAX
PRODUCT, shall terminate on a country-by-country basis and on a product by
product basis on the later of (i) five (5) years after first countrywide
launch of such product in such country or (ii) the expiration of the last to
expire patent (whether or not owned by HGS) on the relevant product licensed
to HGS under this Agreement which covers the making, having made, importing,
offering to sell or using or selling of such product in the country in which
such product was developed, made, sold or used.

      3.13 Royalty obligations under Paragraphs 3.9 and 3.10, with respect to a
COLLABORATION PRODUCT sold by DYAX in the IMAGING FIELD, shall terminate on a
country-by-country basis and on a product by product basis on the later of
(i) ten (10) years after first country-wide launch of such product in such
country or (ii) expiration of the last to expire patent on the relevant
product licensed to DYAX under this Agreement which covers the making, having
made, importing, offering to sell or using or selling of such product in the
country in which such product was developed, made, sold or used.

      3.14 For purposes of this Article 2.10, (a) "Phase III clinical trial"
shall mean a human clinical trial in any country the results of which could be
used as pivotal to establish safety and efficacy of a product as a basis for a
marketing approval application submitted to the FDA or the appropriate
regulatory authority of such other country, or that would otherwise satisfy the
requirements of 21 CFR 312.21(c); and (b) a trial shall be "started" upon the
enrollment of the first patient for such trial. If the nature of a trial earlier
than Phase III is not determined to be pivotal until after completion of the
trial, then any milestone payment that would have been due upon start of a Phase
III trial shall be due upon submission of the trial in support of the filing of
an application for marketing approval in a MAJOR COUNTRY.

      3.15 If, at the time when any milestone payment listed in Paragraph 3.2
with respect to a product is due from HGS, HGS has not paid all other milestone
payments (if any) previously listed in such Paragraph with respect to such
product, then at such time HGS shall pay all such unpaid milestone payments (if
any) previously listed in such Paragraph with respect to such product. If, at
the time of the first commercial sale of a product by HGS or its AFFILIATE, HGS
has not paid all milestone payments (if any) listed in Paragraph 3.2 with
respect to such product, then at such time HGS shall pay all such unpaid
milestone payments (if any) listed in such Paragraph with respect to such
product.

      3.16 In the event that a party or its AFFILIATE sells product to a THIRD
PARTY that also purchases other products or services from such party or its
AFFILIATE, and such party or its AFFILIATE discounts the purchase price of such
product to a greater degree than it generally discounts the price of its other
products to such customer, then in such case the NET SALES for the sale of such
product to such THIRD PARTY shall be deemed to equal the arm's length price that
third parties would generally pay for such product alone when not purchasing any
other product or service from such party or its AFFILIATE. For purposes of this
provision "discounting" includes establishing the list price at a
lower-than-normal level.

                                       9
<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

      3.17 The manner in which statements and remittances of royalty and other
payments are handled is as set forth in Article 8 hereof.

4. COLLABORATION, TECHNOLOGY TRANSFER, TRAINING AND SUPPORT

      4.1 This collaboration between the parties shall be managed by a Steering
Committee, which shall consist of two (2) senior representatives of each party.

            4.1.1 Each party shall notify the other party in writing of its
initial representatives to the Steering Committee within thirty (30) days after
the Effective Date. Each party may substitute one or more representatives from
time to time effective upon written notice to the other party.

            4.1.2 The Steering Committee shall meet in person or by conference
call not less than once a quarter during the COLLABORATION TERM.

      4.2 Within forty-five (45) days of the Effective Date, DYAX will provide
to HGS Dyax Libraries for HGS' research use in the FIELD OF USE. *************.

      4.3 DYAX shall provide training to HGS in the use of such libraries at
either HGS facilities or at DYAX facilities as the parties shall mutually agree.

      4.4 Subject to Paragraph 4.5, DYAX shall provide to HGS at DYAX's
facilities ************* FTEs *************. Such FTEs, at HGS' direction, shall
be available for and may be used: *************.

            4.4.1 DYAX shall appoint a project team which includes a project
leader ("DYAX PROJECT LEADER") to coordinate the work of the ************* FTEs
and such DYAX PROJECT LEADER shall coordinate with an HGS designated project
leader ("HGS PROJECT LEADER") all work to be done pursuant to this Article.

            4.4.2 Within thirty (30) days of the Effective Date, the HGS PROJECT
LEADER, in consultation and collaboration with the DYAX PROJECT LEADER, shall
prepare a six-month work plan for the ************* FTEs.

            4.4.3 The DYAX PROJECT LEADER shall be responsible for coordinating
the ************* FTEs and insuring that all diligent efforts are made to
complete the objectives of the work plan in a timely and efficient manner, and
such work of the DYAX PROJECT LEADER shall be part of the FTEs assigned to HGS.

            4.4.4 At least once a month, the HGS PROJECT LEADER and the DYAX
PROJECT LEADER shall meet in person or by conference call to discuss the
progress made with respect to the work plan, including the capacity of the FTEs
assigned to HGS, and based on that progress, the HGS PROJECT LEADER shall
prepare a work plan for the following six months in consultation and
collaboration with the DYAX PROJECT LEADER.

                                       10
<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

      4.5 Upon 90-day notice to DYAX, HGS may request that DYAX increase the
number of FTEs assigned to HGS. Upon 180 day notice, HGS may request that DYAX
decrease the number of FTEs assigned to HGS, *************.

      4.6 HGS shall pay to DYAX research support payments based on the level of
FTEs assigned to HGS pursuant to Paragraph 4.4, *************. In addition, HGS
shall reimburse DYAX for any mutually agreed upon out-of-pocket external
expenses incurred during the Research Collaboration, provided, however, DYAX
acknowledges that the payment made pursuant to Paragraph 3.1 is intended, among
other things, to cover the costs of any additional facilities and equipment
required to support the ************* FTEs.

      4.7 At any time after the first two years and upon one year's written
notice to the other party, HGS or DYAX may cancel future research support and
the parties' obligations under Paragraphs 4.4 and 4.6 shall terminate.

      4.8 As part of the collaboration and if not in conflict with any of DYAX's
existing agreements, HGS shall have the right to enter into one or more
agreements with DYAX for DYAX in the field of high throughput purification of
HGS TARGETS *************, and to discover and develop affinity ligands for the
separation and purification of HGS products or HGS TARGETS for clinical and
commercial use on standard affinity ligand development terms as set forth in
Exhibit C to this Agreement.

5. CONFIDENTIALITY

      5.1 During the term of this Agreement and for a period of five (5)
years following the expiration or earlier termination hereof, each party
shall maintain in confidence the CONFIDENTIAL INFORMATION of the other party,
and shall not disclose, use or grant the use of the CONFIDENTIAL INFORMATION
of the other party except on a need-to-know basis to such party's AFFILIATES,
directors, officers and employees, and such party's consultants and
collaborators, to the extent such disclosure is reasonably necessary in
connection with such party's activities as expressly authorized by this
Agreement. To the extent that disclosure to any person is authorized by this
Agreement, prior to disclosure, a party shall obtain written agreement of
such person to hold in confidence and not disclose, use or grant the use of
the CONFIDENTIAL INFORMATION of the other party except as expressly permitted
under this Agreement. Each party shall notify the other party promptly upon
discovery of any unauthorized use or disclosure of the other party's
CONFIDENTIAL INFORMATION. Upon the expiration or earlier termination of this
Agreement, each party shall return to the other party all tangible items
regarding the CONFIDENTIAL INFORMATION of the other party and all copies
thereof; provided, however, that each party shall have the right to retain
one (1) copy for its legal files for the sole purpose of determining its
obligations hereunder.

      5.2 No public announcement concerning (i) the existence or terms of this
Agreement, (ii) research and/or discoveries made by one party, (iii) milestones
achieved by one party, or (iv) exercise by one party of rights and options
granted under this Agreement, shall be made, either directly or indirectly, by
any other party to this Agreement without prior written notice and, except as
may be legally required, or as may be legally required for a public offering of

                                       11
<PAGE>

securities, or as may be required for recording purposes, without first
obtaining the approval of the other party and agreement upon the nature and text
of such announcement, such agreement and/or approval not to be unreasonably
withheld. The party desiring to make any such public announcement shall inform
the other party of the proposed announcement or disclosure at least five (5)
business days prior to public release, and shall provide the other party with a
written copy thereof, in order to allow such other party to comment upon such
announcement or disclosure. This Paragraph shall not apply to any information in
a public announcement that is information essentially identical to that
contained in a previous public announcement agreed to pursuant to this
paragraph.

      5.3 The confidentiality obligations under Paragraphs 5.1 and 5.2 shall not
apply to the extent that a party is required to disclose information by
applicable law, regulation or order of a governmental agency or a court of
competent jurisdiction; provided, however, that to the extent practicable, such
party (a) shall provide advance written notice thereof to the other party and
consult with the other party prior to such disclosure with respect thereto, and
(b) shall provide the other party with reasonable assistance, as requested by
the other party, to object to any such disclosure or to request confidential
treatment thereof, and (c) shall take reasonable action to avoid and/or minimize
the extent of such disclosure.

6. INTELLECTUAL PROPERTY OWNERSHIP

      6.1 Nothing in this Agreement transfers or licenses any right, title or
interest to DYAX PATENT RIGHTS, DYAX TECHNOLOGY or HGS PATENT RIGHTS except as
expressly set out herein. HGS acknowledges that the licenses to the DYAX
TECHNOLOGY AND DYAX PATENT RIGHTS as granted under Paragraph 2.1, 2.2 and 2.4
are non-exclusive and that DYAX has granted and will continue to grant the same
or similar rights to THIRD PARTIES. HGS further acknowledges that DYAX or THIRD
PARTIES may independently discover, make or develop the same or a similar
product as HGS may discover, make or develop under this Agreement.

      6.2 Subject to the rights and licenses granted in this Agreement, DYAX
shall own all general know-how developed by DYAX, DYAX TECHNOLOGY,
IMPROVEMENTS, and DYAX PATENT RIGHTS. HGS shall own all HGS TARGETS, HGS
PATENT RIGHTS, RESEARCH PROGRAM IP, COLLABORATION PRODUCTS, NON-COLLABORATION
PRODUCTS and NON-DYAX PRODUCTS. Both parties hereby assign and agree to
assign any and all rights, title and interest in inventions as necessary to
effectuate the ownership rights set forth in this Paragraph.

      6.3 Nothwithstanding HGS' ownership of RESEARCH PROGRAM IP, HGS agrees
that its rights of use to the RESEARCH PROGRAM IP is limited to conjunction
with the licenses granted in Article 2, except that, in addition to uses in
conjunction with such licenses, HGS shall have the non-exclusive worldwide
royalty-free right to RESEARCH PROGRAM IP, with the right to sublicense, to
research, develop, make, have made, use, import, offer to sell, and sell
products in all fields, other than the FIELD OF USE, the IMAGING FIELD and
the DYAX FIELD. Other than as set forth in Article 2, no license to any DYAX
TECHNOLOGY or DYAX PATENT RIGHTS is granted by this Paragraph, even if such
license is necessary to effectuate the right granted pursuant to this
Paragraph, and no such license to any DYAX PATENT RIGHTS or DYAX TECHNOLOGY
shall be implied.

                                       12
<PAGE>

7. PATENT PROSECUTION AND LITIGATION

      7.1 In connection with the preparation, filing, prosecution (including
oppositions) and maintenance of patents on RESEARCH PROGRAM IP related to a
COLLABORATION PRODUCT for which DYAX has obtained a license under Paragraph
2.5 and 2.7, HGS shall endeavor to obtain commercially reasonable patent
protection (under the circumstances) in the RESEARCH PROGRAM IP and shall
consider in good faith the interests of DYAX in so doing. HGS (a) shall
consult with DYAX regarding the preparation of such patents, and shall
implement all reasonable requests of DYAX; (b) shall supply DYAX with a copy
of each such patent application as filed, together with notice of its filing
date and serial number; (c) shall consult with DYAX regarding the prosecution
and maintenance of such patents, and shall implement all reasonable requests
of DYAX; and (d) shall inform DYAX promptly of the allowance and issuance of
each such patent, together with the date and patent number thereof, and shall
provide DYAX with a copy of such patent as allowed and then as issued; and
(e) shall prosecute all reexaminations and reissues as reasonably requested
by DYAX.

      7.2 If HGS elects to abandon any patent application (for which it does not
file a continuation application), not to pursue the filing of any foreign patent
application or not to maintain any patent directed to a COLLABORATION PRODUCT
for which DYAX has obtained a license under Paragraph 2.5, HGS shall give DYAX
written notice thereof not less than ninety (90) days prior to the last day
permitted to timely continue such patent application or to maintain such patent
and protect its rights under this Paragraph 7.2. DYAX shall have the right, at
its sole cost and in its sole discretion, to assume control of the preparation,
filing, prosecution (including oppositions) and maintenance of such patent
application or patent.

      7.3 Each party shall cooperate with the other, execute all lawful papers
and instruments and make all rightful oaths and declarations as may be
reasonably necessary in the preparation, filing, prosecution and maintenance of
the patents or any other rights related to RESEARCH PROGRAM IP.

      7.4 Both parties will provide the other reasonable assistance to enable
the other to prepare, file, prosecute and maintain patents pursuant to this
Article 7.

      7.5 In the event of the institution of any suit by a THIRD PARTY,

            7.5.1 against DYAX, its AFFILIATES or licensees (other than HGS) to
the extent it is for patent infringement involving the manufacture, use, import,
offer for sale, sale, distribution or marketing of a COLLABORATION PRODUCT,
*************, sold by DYAX its AFFILIATES or licensees (other than HGS) , DYAX
shall promptly notify HGS in writing. As between HGS and DYAX, DYAX shall be
solely responsible for the cost and expense of such action and any liability
that results therefrom.

            7.5.2 against HGS, its AFFILIATES or licensees (other than DYAX) to
the extent it is for patent infringement involving the manufacture, use, import,
offer for sale, sale, distribution or marketing of a COLLABORATION PRODUCT or
NON-COLLABORATION PRODUCT sold by HGS, its AFFILIATES or licensees (other than
DYAX), HGS shall promptly

                                       13
<PAGE>

notify DYAX in writing. As between HGS and DYAX, HGS shall be solely responsible
for the cost and expense of such action and any liability that results
therefrom.

The party defending an action under this Paragraph 7.5 shall have full control
over the conduct of the action, including settlement thereof provided such
settlement shall not be made without the prior written consent of the other
party if it would adversely affect the rights of such other party.

      7.6 In the event that HGS or DYAX becomes aware of actual or threatened
infringement of a patent related to RESEARCH PROGRAM IP that claims a
COLLABORATION PRODUCT or NON-COLLABORATION PRODUCT, or the use thereof, that
party shall promptly notify the other party in writing. The owner of such
patent shall have the first right but not the obligation to bring, at its own
expense, an infringement action against any THIRD PARTY and to use the other
party's name in connection therewith. If the owner of the patent does not
commence a particular infringement action within ninety (90) days, the other
party, after notifying the owner in writing, shall be entitled to bring such
infringement action, in its own name and/or in the name of the patent owner,
at its own expense to the extent that such party is licensed thereunder. The
foregoing notwithstanding, in the event that an alleged infringer certifies
pursuant to 21 U.S.C. ss. 355(b)(2)(A)(iv) against an issued patent related
to RESEARCH PROGRAM IP that claims a COLLABORATION PRODUCT or
NON-COLLABORATION PRODUCT or the use thereof, as between the patent owner and
the owner of the product, the party receiving notice of such certification
shall immediately notify the other party of such certification, and if
fourteen (14) days prior to expiration of the forty five (45) day period set
forth in 21 U.S.C. ss. 355(c)(3)(C), the owner of the patent fails to
commence an infringement action, the party receiving notice, in its sole
discretion, at its own expense and to the extent that it is licensed under
the patent, shall be entitled to bring such infringement action in its own
name and/or in the name of the patent owner. The party conducting an action
under this Paragraph 7.6 shall have full control over its conduct, including
settlement thereof provided such settlement shall not be made without the
prior written consent of the other licensing party or licensed party if it
would adversely affect the rights of such other party. The licensing party
(i.e., the patent owner) and the licensed party (i.e., the owner of the
product) shall reasonably assist one another and cooperate in any such
litigation at the other's request, each such party paying its own costs and
expenses. The party conducting the litigation shall reimburse the other party
for its reasonable and actual out-of-pocket expenses incurred at the request
of the party conducting the litigation for assisting in the litigation, which
reimbursement shall be made within thirty (30) days of receipt by the party
conducting the litigation of itemized invoices from the assisting party
documenting such expenses.

      7.7 Any recovery made by a party as the result of an action for patent
infringement it has conducted under Paragraph 7.6 shall be distributed as
follows:

            (a)   The party conducting the action shall recover its actual
                  out-of-pocket expenses incurred in connection with the
                  prosecution of such action, and then shall reimburse the other
                  party for any unreimbursed actual out-of-pocket expenses.

                                       14
<PAGE>

            (b)   To the extent that the recovery from such action exceeds the
                  total of item (a), the excess shall be kept by the party
                  conducting the action; provided, however, that to the extent
                  that (i) the recovery is based on an award of lost
                  sales/profits, and (ii) the party conducting the action would
                  have incurred a royalty obligation to the other party based
                  upon such sales, the party to whom such royalties would have
                  been due shall receive a proportion of the excess recovery
                  corresponding to the royalty percentage it would have
                  otherwise been due.

      7.8 The parties shall periodically keep one another reasonably informed of
the status of their respective activities regarding any such litigation or
settlement thereof.

8. STATEMENTS AND REMITTANCES

      8.1 DYAX and HGS, as the case may be, shall keep and require its
AFFILIATES and licensees and their distributors to keep complete and accurate
records of all sales and calculations of all amounts owing hereunder. Each party
shall have the right, at its expense, through an independent certified public
accounting firm of nationally recognized standing reasonably acceptable to the
other party, to examine pertinent financial records during regular business
hours upon advance written notice during the life of this Agreement and for
twelve (12) months after its termination for the purpose of verifying and
reporting to HGS or DYAX as to the computation of the payments made hereunder
not more than twenty four (24) months prior to the date of such notice;
provided, however, that such examination shall not take place more often than
once a year; provided further that such accountant shall report only as to the
accuracy of the statements and payments hereunder, including the magnitude and
source of any discrepancy. DYAX, HGS, and their respective AFFILIATES and
licensees and their distributors shall be required to maintain such records for
twenty-four (24) months. The accountant shall execute customary confidentiality
agreements prior to any examination, reasonably satisfactory in form and
substance to both parties, to maintain in confidence all information obtained
during the course of any such examination, except for disclosure to the parties,
as necessary for the above purpose. Each such examination conducted under this
Paragraph 8.1 shall be at the expense of the party conducting such examination,
unless a variation or error producing an increase exceeding ************* of the
amount stated for any period is established in the course of any such
examination, whereupon the reasonable out-of-pocket expenses of conducting such
examination for such period will be paid by the other party.

      8.2 Within sixty (60) days after the close of each calendar quarter, DYAX
and HGS, as the case may be, shall deliver to the other party a true accounting
of all amounts owing hereunder during such calendar quarter and shall at the
same time pay all amounts due.

      8.3 All royalties and other payments due under this Agreement shall be
payable in U.S. dollars.

      8.4 Royalties payable on sales in countries other than the United States
shall be calculated by multiplying the appropriate royalty rate times the sales
in each currency in which

                                       15
<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

they are made and converting the resulting amount into United States dollars, at
the rates of exchange as reported in The Wall Street Journal under the caption
"Currency Trading" on the last business day in New York, New York of each
royalty period. If The Wall Street Journal ceases to be published, then the rate
of exchange to be used shall be that reported in such other business publication
of national circulation in the United States as the parties reasonably agree.
All royalty and other payments shall be without deduction of exchange,
collection, or other charges. If, due to restrictions or prohibitions imposed by
a national or international authority, payments cannot be made as aforesaid, the
parties shall consult with a view to finding a prompt and acceptable solution,
and the parties will deal with such monies as the other party may lawfully
direct at no additional out-of-pocket expense to the party owed the royalty.
Notwithstanding the foregoing, if royalties cannot be remitted for any reason
within six (6) months after the end of the calendar quarter during which they
are earned, then the party owing the royalty shall be obligated to deposit the
royalties in a bank account in the country, in which such royalty was earned, in
the name of the other party. Each party shall deduct any taxes which the party
is obligated to pay and/or withhold in a country based on royalties due to the
other based on sales in such country from royalty payments due for such country
under this Agreement and pay them to the proper authorities as required by
applicable laws. Each party shall maintain official receipts of payment of any
such taxes and forward these receipts to the other within sixty (60) days and
shall provide reasonable assistance to the other party in obtaining any credit
or refund of such taxes.

      8.5 All payments to be made hereunder shall be by wire transfer of
immediately available funds to an account designated by DYAX or HGS, whoever is
to be the recipient of such funds.

      8.6 Any payment due from a party to the other party under this Agreement
that is not paid on the date such payment is due shall bear interest at a rate
per annum equal to the lesser of (a) ************* or (b) the maximum rate
permitted by applicable law, in each case calculated on the number of days such
payment is delinquent. If The Wall Street Journal ceases to be published, then
the prime rate to be used shall be that reported in such other business
publication of national circulation in the United States as the parties
reasonably agree. This Section 8.6 shall in no way limit any other remedies
available to a party.

9. TERM AND TERMINATION

      9.1 This Agreement shall come into effect as of the Effective Date, and
unless earlier terminated as provided in this Article 9, shall remain in full
force and effect until the last to expire of the parties' respective royalty
obligations under this Agreement.

      9.2 A party shall have the right to terminate this Agreement with respect
to any product (a) upon the breach by the other party of the other party's
obligations to pay any amounts owing hereunder with respect to such product, if
such breach is not cured within thirty (30) days after receipt of written notice
from such party thereof. Notwithstanding the foregoing, a party may not
terminate this Agreement during the pendency of an arbitration proceeding under

                                       16
<PAGE>

this Agreement in which the other party reasonably contests whether a royalty or
other amount is due hereunder.

      9.3 A party shall have the right to terminate this Agreement in its
entirety (a) upon the breach by the other party of the other party's obligations
to pay any amounts owing hereunder, if such breach is not cured within thirty
(30) days after receipt of written notice from such party thereof, or (b) upon
the material breach by the other party of the other party's obligations, if such
breach is not cured within sixty (60) days after receipt of written notice from
such party thereof. Notwithstanding the foregoing, a party may not terminate
this Agreement during the pendency of an arbitration proceeding under this
Agreement in which the other party reasonably contests whether a royalty or
other amount is due hereunder, or whether it has failed to satisfy its other
obligations hereunder.

      9.4 Notwithstanding expiration or termination of this Agreement, the
rights and obligations of the parties under Articles 5, 6, 7, 8, 9, 11, and
13, shall survive such expiration or termination, as well as any provision
not specified in this Paragraph 9.4 which is expressly stated to survive
termination of this Agreement. In addition, Paragraphs 2.7 and 2.8 shall
survive expiration or termination of this Agreement unless such agreement is
terminated by HGS as the result of a breach by DYAX. Upon expiration of a
party's royalty obligations under this Agreement with respect to a product,
the licenses granted with respect to such product under DYAX PATENT RIGHTS,
HGS PATENT RIGHTS and RESEARCH PROGRAM IP (as applicable) shall survive on a
non-exclusive basis. Upon termination of this Agreement, whether as to any
product or in its entirety, if the licensee of a party with respect to a
product hereunder requests by written notice to the other party hereunder
within thirty (30) days after the effective date of such termination, the
other party shall grant to such licensee a direct license with respect to
such product on the applicable terms and conditions of this Agreement,
provided that such (sub)licensee agrees in writing to be bound by such terms
and conditions.

      9.5 The provisions of Paragraphs 9.2 and 9.3 shall not limit the rights
and remedies that may be otherwise available to a party under this Agreement, at
law or in equity.

10. WARRANTIES AND REPRESENTATIONS

      10.1 Each of HGS and DYAX hereby represents, warrants and covenants to the
other, as of the date of this Agreement, as follows:

            10.1.1 it is a corporation duly organized and validity existing
under the laws of the state of its incorporation;

            10.1.2 the execution, delivery and performance of this Agreement by
such party has been duly authorized by all requisite corporate action;

            10.1.3 it has the power and authority to execute and deliver this
Agreement and to perform its obligations hereunder, including, without
limitation, the right, power and authority to grant the licenses under Article
2;

                                       17
<PAGE>

            10.1.4 The execution, delivery and performance by such party of this
Agreement and its compliance with the terms and provisions hereof to such
party's best knowledge does not conflict with or result in a breach of any of
the terms and provisions of or constitute a default under (i) a loan agreement,
guaranty, financing agreement, agreement affecting a product or other agreement
or instrument binding or affecting it or its property; (ii) the provisions of
its charter documents or bylaws; or (iii) any order, writ, injunction or decree
of any court or governmental authority entered against it or by which any of its
property is bound;

            10.1.5 This Agreement constitutes such party's legal, valid and
binding obligation enforceable against it in accordance with its terms subject,
as to enforcement, to bankruptcy, insolvency, reorganization and other laws of
general applicability relating to or affecting creditors' rights and to the
availability of particular remedies under general equity principles.

      10.2 After the Effective Date, (a) HGS shall not enter into any agreement,
or amend, modify, restate or waive any provisions of any other agreement to
which it is or becomes a party, that would materially and adversely affect the
rights and licenses granted to DYAX, and (b) DYAX shall not enter into any
agreement, or amend, modify, restate or waive any provisions of any agreement to
which it is or becomes a party, that would materially and adversely affect the
rights and licenses granted to HGS.

      10.3 NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A WARRANTY THAT ANY
PATENT INCLUDED WITHIN DYAX PATENT RIGHTS, HGS PATENT RIGHTS OR RESEARCH PROGRAM
IP ARE VALID OR ENFORCEABLE OR THAT THEIR EXERCISE OR THE EXERCISE OF HGS PATENT
RIGHTS, DYAX PATENT RIGHTS, DYAX TECHNOLOGY or RESEARCH PROGRAM IP PROPERTY DOES
NOT INFRINGE ANY PATENT RIGHTS OF THIRD PARTIES. A HOLDING OF INVALIDITY OR
UNENFORCEABILITY OF ANY SUCH PATENT, FROM WHICH NO FURTHER APPEAL IS OR CAN BE
TAKEN, SHALL NOT AFFECT ANY OBLIGATION HEREUNDER, BUT SHALL ONLY ELIMINATE
ROYALTIES OTHERWISE DUE UNDER SUCH PATENT FROM THE DATE SUCH HOLDING BECOMES
FINAL.

      10.4 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN HGS AND DYAX MAKE NO
REPRESENTATIONS OR EXTEND ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE OR NONINFRINGEMENT.

      10.5 Each party shall use any materials provided by the other party under
this Agreement in compliance with all applicable laws and regulations.

11. INDEMNIFICATION

      11.1 DYAX shall defend, indemnify and hold harmless HGS, its AFFILIATES,
licensors of HGS and each of their respective directors, officers, shareholders,
agents and

                                       18
<PAGE>

employees, from and against any and all liability, loss, damages and expenses
(including reasonable attorneys' fees) as the result of claims, demands, actions
or proceedings by any THIRD PARTY which are made or instituted against any of
them arising out of the development, manufacture, possession, distribution, use,
testing, sale or other disposition of any COLLABORATION PRODUCT by or through
DYAX, its AFFILIATES or any THIRD PARTY granted rights by DYAX under this
Agreement. DYAX's obligation to defend, indemnify and hold harmless shall
include claims, demands, actions or proceedings, whether for money damages or
equitable relief by reason of alleged personal injury (including death) to any
person or alleged property damage, provided, however, the indemnity shall not
extend to any claims against an indemnified party which result from the gross
negligence or willful misconduct of an indemnified party. DYAX shall have the
exclusive right to control the defense of any action which is to be indemnified
in whole by DYAX hereunder, including the right to select counsel reasonably
acceptable to HGS to defend HGS and the indemnified parties hereunder, and to
settle any claim, demand, action or proceeding, provided that, without the prior
written consent of HGS (which shall not be unreasonably withheld or delayed),
DYAX shall not agree to settle any claim, demand, action or proceeding, to the
extent such settlement would have a material adverse effect on HGS. The
provisions of this paragraph shall survive and remain in full force and effect
after any termination, expiration or cancellation of this Agreement and DYAX's
obligations hereunder shall apply whether or not such claims are rightfully
brought. DYAX shall require each (sub)licensee hereunder to agree to indemnify
HGS, in a manner consistent with this Paragraph 11.1.

      11.2 HGS shall defend, indemnify and hold harmless DYAX, its AFFILIATES,
licensors of DYAX and each of their respective directors, officers,
shareholders, agents and employees, from and against any and all liability,
loss, damages and expenses (including reasonable attorneys' fees) as the result
of claims, demands, actions or proceedings by any THIRD PARTY which are made or
instituted against any of them arising out of the development, manufacture,
possession, distribution, use, testing, sale or other disposition of any
COLLABORATION PRODUCT, NON-COLLABORATION PRODUCT or NON-DYAX PRODUCT by or
through HGS, its AFFILIATES or any THIRD PARTY granted rights by HGS under this
Agreement. HGS' obligation to defend, indemnify and hold harmless shall include
claims, demands, actions or proceedings, whether for money damages or equitable
relief by reason of alleged personal injury (including death) to any person or
alleged property damage, provided, however, the indemnity shall not extend to
any claims against an indemnified party which result from the gross negligence
or willful misconduct of an indemnified party. HGS shall have the exclusive
right to control the defense of any action which is to be indemnified in whole
by HGS hereunder, including the right to select counsel reasonably acceptable to
DYAX to defend DYAX and the indemnified parties hereunder and to settle any
claim, demand, action or proceeding, provided that, without the prior written
consent of DYAX (which shall not be unreasonably withheld or delayed), HGS shall
not agree to settle any claim, demand, action or proceeding to the extent such
claim, demand, action or proceeding has a material adverse effect on DYAX. The
provisions of this paragraph shall survive and remain in full force and effect
after any termination, expiration or cancellation of this Agreement and HGS'
obligation hereunder shall apply whether or not such claims are rightfully
brought. HGS shall require each licensee hereunder to agree to indemnify DYAX in
a manner consistent with this Paragraph 11.2.

                                       19
<PAGE>

      11.3 A person or entity that intends to claim indemnification under this
Article 11 (the "Indemnitee") shall promptly notify the other party (the
"Indemnitor") of any claim, demand, action or proceeding for which the
Indemnitee intends to claim such indemnification, and the Indemnitor, after it
determines that indemnification is required of it, shall assume the defense
thereof with counsel selected by the Indemnitor and reasonably acceptable to the
other party; provided, however, that an Indemnitee shall have the right to
retain its own counsel, with the fees and expenses to be paid by the Indemnitor
if the Indemnitor does not assume the defense or if representation of such
Indemnitee by the counsel retained by the Indemnitor would be inappropriate due
to actual or potential conflicts of interest between such Indemnitee and any
other party represented by such counsel in such proceedings. The indemnity
agreement in this Article 11 shall not apply to amounts paid in settlement of
any claim, demand, action or proceeding if such settlement is effected without
the consent of the Indemnitor, which consent shall not be unreasonably withheld
or delayed. The failure to deliver notice to the Indemnitor within a reasonable
time after the commencement of any such action, if prejudicial to its ability to
defend such action, shall relieve such Indemnitor of any liability to the
Indemnitee under this Article 11, but failure to deliver notice to the
Indemnitor will not relieve it of any liability that it may have to any
Indemnitee otherwise than under this Article 11. The Indemnitee under this
Article 11, its employees and agents, shall reasonably cooperate with the
Indemnitor and its legal representatives in the investigations of any claim,
demand, action or proceeding covered by this indemnification. In the event that
each party claims indemnity from the other and one party is finally held liable
to indemnify the other, the Indemnitor shall additionally be liable to pay the
reasonable legal costs and attorneys' fees incurred by the Indemnitee in
establishing its claim for indemnity.

12. FORCE MAJEURE

      12.1 If the performance by a party of any obligation under this Agreement
(other than an obligation for the payment of money) is prevented, restricted,
interfered with or delayed by reason of any reasonably unforeseeable cause
beyond the reasonable control of the party liable to perform, the party so
affected shall, upon giving written notice to the other party, be excused from
such performance to the extent of such prevention, restriction, interference or
delay by such reasonably unforeseeable cause beyond its reasonable control,
provided that the affected party shall use commercially reasonable efforts to
avoid or remove such causes of non-performance and shall continue performance
with the utmost dispatch whenever such causes are removed. When such
circumstances arise, the parties shall discuss what, if any, modification of the
terms of this Agreement may be required in order to arrive at an equitable
solution.

13. DISPUTE RESOLUTION

      13.1 All disputes between the Parties arising out of the circumstances and
relationships contemplated by this Agreement including disputes relating to the
validity, construction or interpretation of this Agreement and including
disputes relating to pre-contractual representations shall be in the first
instance referred to the respective Chief Executive Officers of the Parties. If
they fail to agree then any dispute shall be settled by arbitration as follows:

                                       20
<PAGE>

      13.2 The dispute may be referred by either party for arbitration in
accordance with the provisions of this Article 13 under the guidelines of the
American Arbitration Association ("AAA") in Wilmington, Delaware under the
commercial rules then in effect for AAA, except as otherwise provided for
herein.

            13.2.1 A party shall notify the other in writing should it intend to
initiate arbitration. The parties shall select, by mutual agreement, one
arbitrator within a time period of thirty (30) days after receipt of such
notice. Should no arbitrator be chosen within such period, the AAA shall appoint
the arbitrator within thirty (30) days after the end of such period. Within
thirty (30) days after selection of such arbitrator, each party shall submit to
the arbitrator a proposed resolution of the dispute and the reasons supporting
such resolution. Should either party desire, a joint meeting before the
arbitrator shall be held within thirty (30) days after the end of the above
resolution submission period.

            13.2.2 Within thirty (30) days after the later of (i) the end of the
resolution submission period or (ii) holding of a joint meeting, the arbitrator
shall decide the matter.

            13.2.3 Unless otherwise agreed to by the parties, the arbitrator
shall make such decisions based on the following factors in descending order of
importance: (a) consistency with the provisions of this Agreement; (b)
consistency with the intent of the parties as reflected in this Agreement; and
(c) customary and reasonable provisions included in comparable agreements. The
decision of the arbitrator will be binding upon the parties without the right of
appeal, and judgment upon the decision may be entered in any court having
jurisdiction thereof.

            13.2.4 The parties shall share equally the reasonable documented
cost of such arbitration proceeding, but not the individual cost of the parties
in participating in such proceeding.

      13.3 This Article 13 shall not limit in any way the right of a party to
bring an action (and enforce a judgment) for equitable relief in any court of
competent jurisdiction.

      13.4 This Agreement shall be construed and enforced in accordance with the
laws of the State of Delaware (without reference to the conflicts of law
principles thereof).

14. ENTIRE AGREEMENT

      14.1 This Agreement (including Exhibits A, B and C) constitutes the entire
agreement between the parties regarding the subject matter hereof and supersedes
all previous writings, understandings, representations and agreements, except
for the Development Agreement dated July 7, 1999 between the parties. No terms
or provisions of this Agreement shall be varied or modified by any prior or
subsequent statement, conduct or act of either of the parties, except that the
parties may amend this Agreement by written instruments specifically referring
to and executed in the same manner as this Agreement.

                                       21
<PAGE>

15. NOTICES

      15.1 Any notice required or permitted under this Agreement shall be in
writing, and shall be delivered to the following addresses of the parties:

        HUMAN GENOME SCIENCES, INC.
        9410 Key West Avenue
        Rockville, Maryland 20850
        Attention: Business Development
        Fax: 301-762-5181

        copy to:

        HUMAN GENOME SCIENCES, INC.
        9410 Key West Avenue
        Rockville, Maryland 20850
        Attention: General Counsel
        Fax: 301-309-8439

        DYAX CORP.
        One Kendall Square, BLDG. 600, Suite 623
        Cambridge, Massachusetts 02139
        Attn: CEO
        Fax: 617-225-2501

      15.2 Any notice required or permitted to be given concerning this
Agreement shall be effective upon receipt by the party to whom it is addressed.

16. ASSIGNMENT AND CHANGE OF CONTROL

      16.1 This Agreement and the licenses herein granted shall be binding upon
and inure to the benefit of the parties and their respective permitted assignees
and successors in interest. Neither this Agreement nor any interest hereunder
shall be assignable by a party without the prior written consent of the other
party and any attempted assignment contrary to this Paragraph 16.1 shall be void
and without force and effect. Notwithstanding the foregoing, a party may assign
this Agreement and all of its rights and obligations hereunder to any AFFILIATE
or to any THIRD PARTY in connection with the transfer or sale of all or
substantially all of its business, or to which it may transfer all or
substantially all of its assets to which this Agreement relates, or in the event
of its merger, consolidation, change in control or similar transaction, without
obtaining the consent of the other party, provided that the assigning party
remains liable under this Agreement and that the THIRD PARTY assignee or
surviving entity assumes in writing all of its obligations under this Agreement

      16.2 Notwithstanding Paragraph 16.1, if DYAX is acquired by a
Pharmaceutical Company (as defined below), transfers or sells all or
substantially all of its business or its assets

                                       22
<PAGE>

to which this Agreement relates to such a company, or in the event of its
merger, consolidation, change in control or similar transaction with such a
company, DYAX shall promptly notify HGS of such transfer, sale or other
event. Upon such notice and after discussion with DYAX, HGS, at its option,
may elect to cancel its obligation under Paragraph 2.9 and thereafter shall
have no obligation to notify DYAX of outlicenses pursuant to Paragraph 2.9.
For the purposes of this paragraph, a Pharmaceutical Company shall mean a
pharmaceutical or biotechnology company whose business includes any material
segment involved in the discovery, development and/or enhancement of
pharmaceutical products and their subsequent licensing, production,
distribution and/or sale and/or the carrying out of biological, chemical,
biochemical, pharmaceutical, medical and/or scientific research.

17. COUNTERPARTS

      17.1 This Agreement may be executed in any number of counterparts, and
each such counterpart shall be deemed an original instrument, but all such
counterparts together shall constitute but one agreement.

18. WAIVER

      18.1 Any delay or failure in enforcing a party's rights under this
Agreement or any waiver as to a particular default or other matter shall not
constitute a waiver of such party's rights to the future enforcement of its
rights under this Agreement, nor operate to bar the exercise or enforcement
thereof at any time or times thereafter, excepting only as to an express written
and signed waiver as to a particular matter for a particular period of time.

      18.2 Notwithstanding the foregoing, in the event DYAX or HGS challenges
whether any payments contemplated hereunder (including, without limitation
royalties or milestones) are due, it shall have the right, but not the
obligation, to make such payments under protest (reserving all rights hereunder)
pending resolution of such dispute.

19. INDEPENDENT RELATIONSHIP

      19.1 Nothing herein contained shall create an employment, agency, joint
venture or partnership relationship between the parties hereto or any of their
agents or employees, or any other legal arrangement that would impose liability
upon one party for the act or failure to act of the other party. No party shall
have any power to enter into any contracts or commitments or to incur any
liabilities in the name of, or on behalf of, the other party, or to bind the
other party in any respect whatsoever.

20. FURTHER ACTIONS

      20.1 Each party agrees to execute, acknowledge and deliver such further
instruments and to do all such other acts, as may be necessary or appropriate in
order to carry out the purposes and intent of this Agreement.

      IN WITNESS WHEREOF, the parties, through their authorized officers, have
executed this Agreement as of the Effective Date.

                                       23
<PAGE>

        DYAX CORP.

        BY: /s/ Henry E. Blair
            ------------------------------------------
               Henry E. Blair
               Chairman and Chief Executive Officer

        HUMAN GENOME SCIENCES, INC.

        BY: /s/ Arthur M. Mandell
            ------------------------------------------
               Arthur M. Mandell
               Senior Vice President, Corporate and
                 Business Development

                                       24
<PAGE>

                                    EXHIBIT A
                                  Patent Rights

================================================================================
                    Application/
      Country         Patent No.     Filing Date    Patent No.    Issue Date
      -------         ----------     -----------    ----------    ----------
--------------------------------------------------------------------------------
US                   07/664,989*          3/1/91     5,223,409       6/29/93
--------------------------------------------------------------------------------
US                         9,319         1/26/93     5,403,484        4/4/95
--------------------------------------------------------------------------------
US                    08/057,667         6/18/93     5,571,698       11/5/96
--------------------------------------------------------------------------------
US div                08/415,922          4/3/95     5,837,500      11/17/98
--------------------------------------------------------------------------------
US div                08/993,776        12/18/97
--------------------------------------------------------------------------------
US div                09/192,067        11/16/98
--------------------------------------------------------------------------------
US div                09/192,068        11/16/98
--------------------------------------------------------------------------------
PCT                   US89/03731          9/1/89
                   W09002809 pub         3/22/90
--------------------------------------------------------------------------------
EPO                  89/910702.3          9/1/89       436,597        4/2/97
                    EP436597 pub         7/17/91
--------------------------------------------------------------------------------
EPO div              96/112867.5          8/9/96       Allowed
                      768377 pub     4/16/97 pub
--------------------------------------------------------------------------------
Japan                   89510087          9/1/89
                 JP4502700 (pub)         5/21/92
--------------------------------------------------------------------------------
Canada                   610,176          9/1/89     1,340,288      12/29/98
--------------------------------------------------------------------------------
Ireland                IR89/2834          9/4/89
--------------------------------------------------------------------------------
Israel                     91501          9/1/89         91501       6/11/98
--------------------------------------------------------------------------------
Israel                    3 divs         5/29/97
--------------------------------------------------------------------------------
PCT                   US92/01456         2/27/92
                 W09215677 (pub)         9/17/92
--------------------------------------------------------------------------------
EPO                  92/908057.0         2/27/92
--------------------------------------------------------------------------------
Canada                   2105300         2/27/92
--------------------------------------------------------------------------------
Japan                   92507558         2/27/92
--------------------------------------------------------------------------------
PCT                   US92/01539         2/28/92
                 W09215679 (pub)         9/17/92
--------------------------------------------------------------------------------
EPO                  92/908799.7         2/28/92
--------------------------------------------------------------------------------
Canada                   2105303         2/28/92
--------------------------------------------------------------------------------

================================================================================

                                       25
<PAGE>

================================================================================
Japan                   92508216         2/28/92
--------------------------------------------------------------------------------
EPO                   99201558.6       5/18/99**
================================================================================

* CIP of US SN487,063 filed 3/2/90 which is a CIP of US SN240,160 filed 9/2/88
All Protein Engineering Corporation patent rights have been assigned to Dyax
Corp. **Application assigned to TargetQuest B.V., a wholly-owned subsidiary of
Dyax Corp.

                                       26
<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

                                    EXHIBIT B

*************

                                       27
<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

                                    EXHIBIT C

                              DEVELOPMENT AGREEMENT

THIS AGREEMENT, effective as of ______, 2000 (the "Effective Date"), is made by
and between DYAX CORP., a Delaware corporation ("DYAX"), and _________________,
a ________corporation ("CUSTOMER").

WHEREAS DYAX possesses technology and expertise related to the discovery of
proteins and peptides having novel binding properties and the development and
manufacture of affinity chromatography purification media for use in the
separation and purification of proteins;

WHEREAS CUSTOMER is engaged in the discovery, development and manufacture of
[description of each customer product] ( "Customer Product");

WHEREAS DYAX and CUSTOMER wish to enter into a collaboration in which DYAX will
utilize its technology and expertise to develop unique affinity ligands and
chromatography purification media (the "Dyax Product") for use by CUSTOMER in
the purification of the Customer Product.

NOW, HEREBY the parties do hereby agree as follows:

                      ARTICLE 1. DISCOVERY AND DEVELOPMENT

1.1. Project Plan. The Project Plan, which is attached hereto and incorporated
herein by reference, sets forth a description of the Customer Product, a
description of the work to be undertaken by DYAX in connection with the
discovery, evaluation and development of the Dyax Product candidates, an
estimated timeline, the amount of compensation due DYAX for such work, and the
specification and payment amount for the performance milestones from such work.
The Project Plan shall be considered an integral part of this Agreement.

1.2. Conduct of Work. DYAX agrees to devote commercially reasonable resources
and efforts to the diligent conduct of the work described in the Project Plan.
CUSTOMER agrees to provide the materials set forth in the Project Plan to DYAX
in a timely manner and to cooperate with DYAX in the review and selection of
Dyax Product candidates and in the evaluation of such candidates. During the
course of the work, DYAX's representatives shall consult with representatives of
CUSTOMER at the reasonable request of CUSTOMER to respond to questions and
facilitate the exchange of appropriate information on the progress of the
Project Plan.

1.3. Project Plan Fee. In consideration of the performance by DYAX of the work
set forth in the Project Plan, CUSTOMER agrees to pay DYAX the project fee
specified in the Project Plan, *************.

                                       28
<PAGE>

Confidential material omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omissions.

1.4. Selection of Dyax Product candidates. DYAX shall provide CUSTOMER with a
report identifying Dyax Product candidates. CUSTOMER shall have a period of
************* from receipt of the report to select Dyax Product candidates for
evaluation. CUSTOMER agrees to pay the media development fee set forth in the
Project Plan for each Dyax Product candidate that CUSTOMER selects for
evaluation. *************.

1.5 Evaluation Period and Milestone Payment. CUSTOMER shall have a period of
30 days from delivery of the media for the selected candidates to undertake
the necessary experiments to reasonably verify whether the milestone set
forth in the Project Plan has been met. CUSTOMER agrees to pay DYAX the
milestone payment set forth in the Project Plan upon the earlier of
verification by CUSTOMER that the milestone has been met or notification by
CUSTOMER to DYAX of its intent to acquire a license as set forth in Article 2.

                        ARTICLE 2. RIGHTS TO DYAX PRODUCT

2.1 Exclusive License Rights. Within ************* following the delivery of the
media for the selected Dyax Product candidates to CUSTOMER, CUSTOMER shall
notify DYAX whether it wishes to acquire an exclusive license to, and be
supplied with, any Dyax Product solely for the purpose of the purification of
the Customer Product. If the milestone payment required by paragraph 1.5 has not
yet been paid at the time of giving of such notice, CUSTOMER shall include the
payment with the notice. The parties shall then promptly negotiate in good faith
the terms and conditions of an exclusive license for the applicable Dyax Product
which shall include the following payment and supply terms: *************. Any
decision to license the Dyax Product to CUSTOMER for the purification of the
Customer Product on a non-exclusive basis shall be at the sole discretion of
DYAX and shall contain such payment and supply terms that may be mutually agreed
upon by the parties.

2.2 Research License In the event that CUSTOMER is not prepared to make a
commitment to an exclusive license pursuant to Section 2.1, CUSTOMER may notify
DYAX within ************* following the delivery of the media for the selected
Dyax Product candidates of its desire to acquire a one year Research License.
Upon giving such notice, the parties shall promptly negotiate in good faith the
terms and conditions of a one year Research License which shall include
immediate payment to DYAX of a license fee *************, the limitations of the
license right and the ability of CUSTOMER to obtain research and development
services from DYAX at DYAX's full time equivalent rate.

                       ARTICLE 3. CONFIDENTIAL INFORMATION

3.1. Disclosure of Confidential Information.

      (a) In connection with the performance of their respective obligations
under this Agreement, each party intends to disclose certain confidential
information and materials which it owns to the other party relating to the
Customer Product and the Dyax Products and the Dyax Product candidates,
including such information and materials as are developed hereunder ( the
"Confidential Information"). During the term of this Agreement and for a period
of (5) years thereafter,

                                       29
<PAGE>

each party shall maintain all Confidential Information in strict confidence,
except that the Receiving Party may disclose or permit the disclosure of any
Confidential Information to its directors, officers, employees, consultants,
advisors, and customers who are obligated to maintain the confidential nature of
such Confidential Information and who need to know such Confidential Information
for the purposes set forth in this Agreement; and use all Confidential
Information solely for the purposes set forth in this Agreement.

      (b) The obligations of confidentiality and non-use set forth above shall
not apply to the extent that the Receiving Party can demonstrate that certain
Confidential Information: was in the public domain prior to the time of its
disclosure under this Agreement; entered the public domain after the time of its
disclosure under this Agreement through means other than an unauthorized
disclosure resulting from an act or omission by the Receiving Party; was
independently developed or discovered by the Receiving Party prior to the time
of its disclosure under this Agreement; or is or was disclosed to the Receiving
Party at any time, whether prior to or after the time of its disclosure under
this Agreement, by a third party having no fiduciary relationship with the
Disclosing Party and having no obligation of confidentiality with respect to
such Confidential Information; or is required to be disclosed to comply with
applicable laws or regulations, or with a court or administrative order.

      (c) Notwithstanding the foregoing, the parties may each announce the
existence of this Agreement and that CUSTOMER is a customer of DYAX provided
that the language of any such announcement shall be agreed to in advance by the
parties.

                        ARTICLE 4. INTELLECTUAL PROPERTY

4.1. Definitions. As used in this Agreement, the term "Invention" means any
development, conception, technique, process, invention, material, discovery, or
improvement, whether or not patentable, that arises as a result of the
performance of this Agreement. "Dyax Invention" shall mean an Invention that is
discovered, developed, conceived, or reduced to practice during this Agreement
and which relates to the Dyax Products or Dyax Product candidates and their
derivatives, including the phage display libraries and technology, and affinity
ligands and media, and the sequence, characteristic and performance information
thereof. "Customer Invention" shall mean an Invention, other than a Dyax
Invention, that is discovered, developed, conceived, or reduced to practice
during this Agreement and which relates to the Customer Product.

6.2. Ownership & Rights to Intellectual Property. DYAX shall have sole ownership
and control of all Dyax Inventions. CUSTOMER shall have sole ownership and
control of all Customer Inventions. Each party's rights to any Invention of the
other shall be governed by this Agreement and by any exclusive license and
supply agreement for the use by CUSTOMER of a Dyax Product in the purification
of the Customer Product or by any research license, either of which may be
entered into by the parties pursuant to Article 2 of this Agreement.

                         ARTICLE 5. TERM AND TERMINATION

                                       30
<PAGE>

5.1. Term. This Agreement shall commence on the Effective Date and continue
until termination pursuant to this Article 5 or as a result of CUSTOMER'S
decision not to proceed with any license pursuant to Article 2 of this
Agreement.

5.2. Termination by CUSTOMER. Provided that CUSTOMER has made all payments
specified in this Agreement which have become due and payable, CUSTOMER shall
have the right to terminate this Agreement at any time by giving 90 days written
notice to DYAX. CUSTOMER agrees to promptly pay DYAX for uncompensated costs and
milestone payments for work completed by DYAX prior to the termination date,
including for any work done during the 90- day termination notice period.
CUSTOMER agrees that no refund of any sums paid to DYAX shall be due upon any
such termination.

5.3. Termination for Material Breach. This Agreement may be terminated by either
party upon 90 days written notice to the other party if any provision hereof is
materially breached, unless such breach is corrected or reasonable efforts are
being made to correct such breach within the 90-day notice period.

5.4. Consequences of Termination and Survival. Upon termination any rights
granted to CUSTOMER under this Agreement shall cease and CUSTOMER shall return
any Dyax Products or Dyax Product candidates to DYAX. DYAX will have the
unrestricted and exclusive right to any Dyax Product, Dyax Product candidates,
Dyax Inventions and the results of the Project Plan. Termination of this
Agreement shall not relieve either party of its obligations incurred prior to
termination. The provisions of Article 3. and Article 4. and Section 6.4 shall
survive expiration or termination of this Agreement.

                          ARTICLE 6. GENERAL PROVISIONS

6.1. Notices. Any notices permitted or required by this Agreement shall be sent
by facsimile, registered mail or a recognized private mail carrier service and
shall be effective when received if sent and addressed as follows or to such
other address as may be designated by a party in writing:

    If to DYAX:                          President, Separations Division
                                         Dyax Corp.
                                         One Kendall Square, Bldg. 600
                                         Cambridge, MA  02139
                                         Telephone:   (617) 225-2500
                                         Fax:         (617) 225-2501

    If to CUSTOMER:                      _________________________
                                         _________________________
                                         _________________________
                                         Attention: ____________
                                         Telephone:   (__)___________

                                       31
<PAGE>

                                         Fax:         (__)___________

6.2. Entire Agreement; Amendment. This Agreement set forth the entire
understanding of the parties with respect to the subject matter hereof and
supersedes all prior agreements, written and oral, between the parties. No
modification of any of the terms of this Agreement shall be deemed to be valid
unless it is in writing and signed by the party against whom enforcement is
sought.

6.3. Force Majeure. Neither party shall be held liable or responsible to the
other party nor be deemed to have defaulted under or breached this Agreement for
failure or delay in performing any term of this Agreement when such failure or
delay is caused by or results from causes beyond the reasonable control of the
affected party, including but not limited to fire, floods, embargoes, war, acts
of war (whether war is declared or not), riots, strikes, lockouts or other labor
disturbances, lawsuits, acts of God or acts, omissions or delays in acting by
any court, governmental authority or the other party.

6.4. Warranties. WITH RESPECT TO ANY DYAX PRODUCT CANDIDATE OR DYAX PRODUCT,
DYAX DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, WHETHER EXPRESSED OR IMPLIED,
INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
A PARTICULAR PURPOSE, ANY WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF
TRADE OR ANY WARRANTIES OF PATENT VALIDITY OR FREEDOM OF OR FROM PATENT
INFRINGEMENT. Neither party shall be liable to the other for consequential,
incidental, indirect or punitive damages arising from the performance or
nonperformance of such party under this Agreement.

6.5. Waiver; Severability. No waiver by either party of any default, right or
remedy shall be effective unless in writing, nor shall any such waiver operate
as a waiver of any other or of the same default, right or remedy, respectively,
on a future occasion. In the event that any term or provision of this Agreement
shall violate any applicable statute, ordinance or rule of law in any
jurisdiction in which it is used, such provision shall be ineffective to the
extent of such violation without invalidating any other provision hereof.

6.6. Assignment. This Agreement may not be assigned or otherwise transferred by
either party without the consent of the other party; provided, however, that
either DYAX or CUSTOMER may, without such consent, assign its rights and
obligations under this Agreement (i) in connection with a corporate
reorganization to an affiliate, all or substantially all of the equity interest
of which is owned and controlled by such party or its parent corporation, or
(ii) in connection with a merger, consolidation or sale of substantially all of
such party's assets to an unrelated third party. Any permitted assignee shall
assume all obligations of its assignor under this Agreement.

6.7. Independent Parties. This Agreement shall not be deemed to create any
partnership, joint venture, or agency relationship between the parties. Each
party hereto is acting as an independent contractor.

6.8. Governing Law. This Agreement shall be governed by and construed under the
laws of the Commonwealth of Massachusetts.

                                       32
<PAGE>

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first written above.

DYAX CORP.                          _____________________

By:____________________________     By: ____________________________
Title: ________________________     Title: _________________________

                                       33<PAGE>

                                                                    EXHIBIT 10.1

                                 AMENDMENT NO. 1
                                     TO THE
                              BMC INDUSTRIES, INC.
                 RESTATED AND AMENDED 1994 STOCK INCENTIVE PLAN

                  Effective August 3, 2000, the BMC Industries, Inc. Restated
and Amended 1994 Stock Incentive Plan (the "1994 Plan") shall be amended as
follows:

         Section 8.1 of the 1994 Plan is amended to include the following
additional clause at the end of the second to last sentence of such Section:

         "; provided that any restriction or condition based solely on years of
         service shall be for at least a period of three years and any
         restriction or condition based on performance shall be for at least a
         period of one year."

         Section 18 of the 1994 Plan is amended to include the additional clause
at the end of the first sentence of such Section:

         "; provided that no change shall be made that increases the total
         number of shares of Common Stock reserved for issuance pursuant to
         Options granted under the Plan (except pursuant to Section 3.3(b), 4.3
         and 13 of the Plan), materially modifies the requirements as to
         eligibility for participation under the Plan, or materially increases
         the benefits accruing to participants under the Plan, including the
         repricing of any previously granted Options, cancellation of
         outstanding Options with subsequent replacement or regrant of Options
         with lower exercise prices, unless such change is authorized by
         shareholders of the Company."

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]